Edesa Biotech, Inc. · NASDAQ:EDSA

Edesa Biotech — Investor Presentation (March 2021)

35 slides from Edesa Biotech's investor presentation, Mar 22, 2021

  1. Slide 1: Corporate Presentation

    Corporate Presentation Edesa Biotech, Inc. March 2021 Nasdaq: EDSA

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such a

  3. Slide 3: Key Investment Highlights

    Key Investment Highlights Multiple clinical stage assets Validated technology Novel MOA approaches; biologics Recipient of federal Strategic Innovation and small molecule Fund reimbursement grant Sector Immune modulation Biotechnology Strong financial backing therapies and Headquarters inflammatory

  4. Slide 4: Technology Acquisition and Targeting

    Technology Acquisition and Targeting Identify overlooked clinical assets with promising growth potential Edesa’s product development strategy is focused primarily on later-stage assets Well Understood Unique Targets Novel Data-Driven Pathway on Pathway Method of Action Indication Priority  Arachido

  5. Slide 5: Edesa Development Pipeline

    Edesa Development Pipeline Advancing and Expanding Our Growth Opportunities Drug Indications Pre-Clinical Phase 1 Phase 2 Phase 3 Status/Milestones Candidates EB01 Allergic Contact First Cohort Fully Enrolled sPLA2 Inhibitor Dermatitis Govt. Grant Awarded / EB05 ARDS and Enrollment Ongoing Anti-TLR4

  6. Slide 6: Acute Respiratory Distress Syndrome

    Acute Respiratory Distress Syndrome EB05 Monoclonal Antibody Therapy Phase 2/3

  7. Slide 7: Strategic Innovation Fund Award

    Strategic Innovation Fund Award Validation of Edesa’s EB05 Technology  C$14 million (US$11m) reimbursement grant awarded by the Canadian Govt.  Following highly competitive, multi-disciplinary review of our plans and technology  Funding for Phase 2 portion of Phase 2/3 study of EB05  Continued e

  8. Slide 8: Acute Respiratory Distress Syndrome (ARDS)

    Acute Respiratory Distress Syndrome (ARDS) Leading Cause of Death in COVID-19 Patients  A life-threatening form of respiratory failure  Exaggerated immune response  Inflammation and injury to the lungs  Edema that deprives the body of oxygen  Other causes  Sepsis, bacterial and viral infection

  9. Slide 9: TLR4 in Severe COVID-19

    TLR4 in Severe COVID-19 Levels of TLR4 are Elevated in Severe COVID-19 Disease Key Role of Toll-like Receptor 4 TLR4 Upregulated in COVID-19 Lung Tissue*  Part of the innate immune response  Receptor for oxidized phospholipids, calprotectins and high-mobility group proteins  A Nobel prize was awa

  10. Slide 10: EB05 Program

    EB05 Program A Potential First-in-Class TLR-4 Pathway Inhibitor TLR4  EB05 is a clinical-stage anti-TLR4 monoclonal Stable Complex antibody (mAb)  Binds specifically to TLR4 with high affinity  Blocks receptor activation by interfering with TLR4 dimerization in a ligand-independent manner  Admin

  11. Slide 11: Evidence of Activity in Humans

    Evidence of Activity in Humans EB05 Inhibited “Cytokine Storm” after In Vivo LPS Challenge IL-6 Serum Concentration (pg/mL) TNF-α Serum Concentration (pg/mL) CXCL10 Serum Concentration (pg/mL) 250 9000 1200 8000 1000 200 7000 CXCL10 (pg/ml) 6000 TNFα (pg/ml) 800 150 IL6 (pg/ml) 5000 600 4000 100 300

  12. Slide 12: Evidence of Activity in Humans

    Evidence of Activity in Humans EB05 Lowered Fever and Stabilized Vital Signs after In Vivo LPS Challenge Mean Change from Baseline of Temperature Mean Change from Baseline of Heart Rate 1.6 30 Change from Baseline (Degrees C) 1.4 25 Change from Baseline (HR bpm) 1.2 20 1 15 0.8 10 0.6 5 0.4 0 0.2 0

  13. Slide 13: Overview of Clinical Trial Design

    Overview of Clinical Trial Design A Phase 2/3 Adaptive Design to Treat Hospitalized COVID-19 Patients Efficacy of EB05 mAb in Subjects  Sequential adaptive design with interim Hospitalized with COVID-19 Infection analysis at end of Phase 2 EB05 (15mg/Kg) + SOC  Targeting hospitalized COVID-19 pati

  14. Slide 14: Allergic Contact Dermatitis

    Allergic Contact Dermatitis EB01 sPLA2 Inhibitor Phase 2b

  15. Slide 15: Allergic Contact Dermatitis

    Allergic Contact Dermatitis Disease State and Current Treatments Allergic Contact Dermatitis (ACD) is a Type IV hypersensitivity reaction Current Limited Treatment Approaches for ACD Safety Issues Often Result in Discontinuation of Treatment  Immune system sensitized with initial contact with aller

  16. Slide 16: Contact Dermatitis

    Contact Dermatitis One of the most prevalent skin conditions in U.S. Claims-Based Prevalence of Skin Disease in the U.S. 9.0% 8.0%  A leading occupational illness  Affecting 13.2 million people in U.S. 7.0%  Cost of up to ~$2 billion annually 6.0%  ACD represents a submarket of 5.0% contact derm

  17. Slide 17: Occupational Contact Dermatitis

    Occupational Contact Dermatitis Adversely Impacts Both Employers and Employees Industry Substances  Loss of Productivity  Physical and emotional distress Agriculture Daffodils, tulips, carrots, parsnips, parsley, celery  Multiple physician visits Chemical Adhesives, paints, acrylates, acids/bases

  18. Slide 18: Novel Approaches to Chronic Conditions

    Novel Approaches to Chronic Conditions Treating Inflammation without the Safety Concerns of Current Therapies  Inhibiting the Inflammation Cascade  sPLA2 inhibitors are designed to inhibit the inflammatory process at its inception  Exerts its anti-inflammatory activity upstream of currently appro

  19. Slide 19: EB01 Efficacy in Humans Established

    EB01 Efficacy in Humans Established Phase 2 Study Demonstrated Efficacy & Safety in ACD Patients Mean Percent Improvement from Baseline in Total CDSI Score Phase 2 Efficacy Study of EB01 60 55.73% For the treatment of allergic contact dermatitis (30 Patients Bilateral Design) 50 48.62% Efficacy At D

  20. Slide 20: Phase 2 Efficacy Study – Breakdown by Component

    Phase 2 Efficacy Study – Breakdown by Component EB01 Addressed All Aspects of CDSI Composite Score Percent Reduction in Symptoms from Baseline to Day 21* P Value = <0.001 81% P Value = <0.001 62% P Value = <0.001 P Value = <0.001 P Value = <0.001 48% 47% 46% 45% 25% 20% 20% 15% Scaling Redness Pruri

  21. Slide 21: Market Survey Reinforces Edesa's Approach

    Market Survey Reinforces Edesa’s Approach Physicians Most Impressed with Non-Steroidal Method of Action Physician-Perceived Strengths of EB01  Key opinion leaders expressed a high desire for additional treatment options for Non-Steroidal Method of Action Novel anti-inflammatory product(MoA) (MoA) 4

  22. Slide 22: EB01 Phase 2b Study

    EB01 Phase 2b Study Adaptive Design up to 166 Patients Patients with ACD EB01 2.0% (n=23) Primary Efficacy Endpoint Part A Mean Percent Change from Baseline in N=~46 Subjects Randomized (1:1) Placebo (n=23) Contact Dermatitis Severity Index (CDSI) at Day 29 Protocol  EB01 evaluated in a randomized,

  23. Slide 23: Hemorrhoids Disease

    Hemorrhoids Disease EB02 sPLA2 Inhibitor Phase 2 Ready

  24. Slide 24: Hemorrhoids Disease (HD)

    Hemorrhoids Disease (HD) Extension of sPLA2 Anti-Inflammatory Tech Treatments of Internal Hemorrhoids2  12.5 million adults affected in U.S.1 Based on their Severity and Degree of Prolapse  By 50 years old, ~50% have Grade 1 Grade 2 Grade 3 Grade 4 Complicated experienced symptomatic hemorrhoids 

  25. Slide 25: EB02 Program

    EB02 Program Targeting clinical relief of itching, pain and thrombosis of HD  Multifactorial etiology of HD  Inflammation involving the vascular wall and surrounding connective tissue  Hyper-perfusion of hemorrhoid plexus  Prolapse  Hemorrhoidal tissue contains  Inflammatory cells and  Newly

  26. Slide 26: EB02 Proof of Concept Phase 2a Study Plan

    EB02 Proof of Concept Phase 2a Study Plan Efficacy of EB02 Cream in Subjects with Protocol Grade I, II or III Internal Hemorrhoids  EB02 will be evaluated in a randomized, double-blind, placebo- controlled, two stage design. Patients with HD EB02 2.0% (n=24) Stage 1  Patients will be treated for 1

  27. Slide 27: Vitiligo and Other Autoimmune Diseases

    Vitiligo and Other Autoimmune Diseases Producing mAbs for Novel Targets

  28. Slide 28: Vitiligo and Other Autoimmune Diseases

    Vitiligo and Other Autoimmune Diseases Developing Immunotherapies for Novel Targets  Vitiligo prevalence: ~1% globally across most racial 1 groups Vitiligo is a disorder in which the immune system  Not merely cosmetic: chronic organ-specific autoimmune attacks and destroys melanocytes in the skin

  29. Slide 29: Corporate Highlights

    Corporate Highlights Milestones Financial Summary Capitalization Leadership

  30. Slide 30: Recent Highlights, Milestones & Strategic Objectives

    Recent Highlights, Milestones & Strategic Objectives PHASE 2/3 COVID-19 STUDY STRATEGIC TRANSACTION & IND & CTA approval DEVELOP NEW MARKETS CAPITALIZATION Manufacturing of drug product Vitiligo project initiation Reverse acquisition / Nasdaq listing 50% enrollment of Phase 2 portion Capital raise M

  31. Slide 31: Cash Position

    Cash Position Balance sheet Selected Financials As of December 31, 2021  Working capital focused on clinical programs Cash & Cash Equiv.* $ 6.3 M  $11 million (C$14m) reimbursement grant Total Assets $ 10.8 M from federal Strategic Innovation Fund  $10m equity offering – March 2020 Working Capita

  32. Slide 32: Capitalization Table

    Capitalization Table As of March 2, 2021 Common Shares and Weighted Average Description Common Share Exercise Price Equivalents Common Shares 13,178,442 A-1 Convertible Preferred Shares $2.26 68,117 Options Outstanding1 $4.76 1,085,387 Warrants $5.65 760,290 Fully Diluted Shares 15,092,236 1 2019 Eq

  33. Slide 33: Holders of Common Shares

    Holders of Common Shares Simplified Beneficial Ownership Table as of March 2020 Percent Shares Percent Holders Shares Outstanding Share Options Warrant Shares Fully Diluted Early Series Financing from Life Science Directors and Officers Specialists Par Nijhawan 3,261,785 24.6% 109,110 6,942 22.4% Lo

  34. Slide 34: Experienced Leadership Team

    Experienced Leadership Team Pharmaceutical Pipelines, Corporate Development & Strategic Transactions Senior Management Team Par Nijhawan, MD, FRCPC, AGAF Board-certified gastroenterologist and hepatologist • Successful track record of building life science businesses, including CEO and Board Directo

  35. Slide 35: Company Contacts

    Company Contacts Par Nijhawan Chief Executive Officer Michael Brooks President Gary Koppenjan Investor Relations Edesa Biotech, Inc. 100 Spy Court Markham, Ontario L3R 5H6 +1 (289) 800-9600 [email protected] www.EdesaBiotech.com

Edesa Biotech — Investor Presentation (March 2021) on 6ix